Aclaris Therapeutics, Inc.(ACRS)

$5.92—

Chart

Aclaris Therapeutics, Inc.(ACRS)

NASDAQ

$5.92—

Chart Studio

ACRS(ACRS)

ACRS

Overview Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.17

Nov 5, 2026 · Reports before open

Revenue Estimate

$1M

Analyst Sentiment

Wall St. Consensus

Buy

16 analysts·Moderate coverage

Score

13 Buy (81%)3 Hold (19%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

1381%

Hold

319%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$10.00

+68.9%

Consensus

$10.50

+77.4%

Bull

$12.00

+102.7%

12-Month Target Range16 analysts

$10.00$10.50$12.00

Current $5.92Consensus

Current Price

$5.92

Upside to Consensus

$4.58

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-0.56%

EPS—

FY2028

Rev+18.05%

EPS—

FY2029

Rev+311.31%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$6M	$6M	$7M	$28M	$114M
Low	$3M	$873,488	$3M	$11M	$43M
High	$9M	$11M	$11M	$43M	$175M
EBITDA Avg	$-6M	$-6M	$-7M	$-28M	$-114M
Low	$-9M	$-11M	$-11M	$-43M	$-175M
High	$-3M	$-873,488	$-3M	$-11M	$-43M
EBIT Avg	$-6M	$-6M	$-7M	$-28M	$-114M
Low	$-9M	$-11M	$-11M	$-43M	$-175M
High	$-3M	$-873,488	$-3M	$-11M	$-43M
Net Income Avg	$-85M	$-105M	$-78M	$-100M	$-84M
Low	$-100M	$-190M	$-113M	$-170M	$-142M
High	$-62M	$-52M	$-43M	$-19M	$-16M
EPS Avg	$-0.67	$-0.78	$-0.77	$-0.82	$-0.68
Low	$-0.81	$-1.55	$-0.92	$-1.38	$-1.16
High	$-0.50	$-0.42	$-0.35	$-0.16	$-0.13
Analysts (Rev / EPS)	8 / 8	8 / 9	7 / 7	3 / 2	5 / 4

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027	Q1 2028	Q2 2028
Revenue Avg	$1M	$1M	$1M	$1M	$1M	$2M	$2M	$2M
Low	$189,850	$1M	$198,581	$207,092	$209,929	$212,765	$283,120	$283,120
High	$2M	$1M	$2M	$2M	$2M	$3M	$3M	$3M
EBITDA Avg	$-1M	$-1M	$-1M	$-1M	$-1M	$-2M	$-2M	$-2M
Low	$-2M	$-1M	$-2M	$-2M	$-2M	$-3M	$-3M	$-3M
High	$-189,850	$-1M	$-198,581	$-207,092	$-209,929	$-212,765	$-283,120	$-283,120
EBIT Avg	$-1M	$-1M	$-1M	$-1M	$-1M	$-2M	$-2M	$-2M
Low	$-2M	$-1M	$-2M	$-2M	$-2M	$-3M	$-3M	$-3M
High	$-189,850	$-1M	$-198,581	$-207,092	$-209,929	$-212,765	$-283,120	$-283,120
Net Income Avg	$-24M	$-24M	$-27M	$-29M	$-31M	$-34M	$-12M	$-13M
Low	$-33M	$-33M	$-50M	$-53M	$-58M	$-64M	$-23M	$-24M
High	$-16M	$-17M	$3M	$3M	$4M	$4M	$1M	$1M
EPS Avg	$-0.17	$-0.17	$-0.19	$-0.20	$-0.22	$-0.24	$-0.09	$-0.09
Low	$-0.23	$-0.23	$-0.35	$-0.37	$-0.40	$-0.45	$-0.16	$-0.17
High	$-0.11	$-0.12	$0.02	$0.02	$0.03	$0.03	$0.01	$0.01
Analysts (Rev / EPS)	7 / 7	9 / 9	7 / 6	4 / 3	4 / 3	7 / 6	7 / 8	3 / 4

Earnings Surprises

Recent Analyst Actions

May 5, 2026Piper Sandler

Aclaris Therapeutics price target raised to $11 from $7 at Piper Sandler

Target:$11.00

+142.8%from $4.53

May 5, 2026Guggenheim

Aclaris Therapeutics initiated with a Buy at Guggenheim

Target:$12.00

+164.9%from $4.53

Apr 29, 2026Wedbush

Aclaris Therapeutics price target raised to $10 from $8 at Wedbush

Target:$10.00

+137.0%from $4.22

Apr 16, 2026UBS

Aclaris Therapeutics initiated with an Outperform at Oppenheimer

Target:$10.00

+154.5%from $3.93

Jan 30, 2026Craig-Hallum

Craig-Hallum bullish on Aclaris Therapeutics, initiates with a Buy

Target:$10.00

+191.5%from $3.43

Nov 19, 2024BTIG

BTIG Upgrades Aclaris Therapeutis (ACRS) to Buy

Target:$8.00

+154.8%from $3.14

Nov 19, 2024Jefferies

Jefferies Upgrades Aclaris Therapeutis (ACRS) to Buy

Target:$7.00

+122.9%from $3.14

Nov 6, 2024Stifel Nicolaus

Aclaris Therapeutis (ACRS) PT Raised to $3 at Stifel

Target:$3.00

+31.9%from $2.27

Dec 1, 2022Goldman Sachs

Goldman Sachs Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $25

Target:$25.00

+64.3%from $15.22

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance